Anastasia Dmitrieva
Interleukin-1 (IL-1), a central mediator of innate immunity and inflammation, plays a pivotal role in a broad spectrum of inflammatory diseases. RPH-104 is a novel IL-1 antagonist: a heterodimer comprised of human extracellular portions of IL-1RI and IL-1 receptor accessory protein, each linked to a mutant Fc portion of human IgG1. Aim: The aim of the studies is preclinical characterization of RPH-104.
இந்தக் கட்டுரையைப் பகிரவும்
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 